Berberine in the treatment of radiation-induced skin injury: insights from proteomics and network pharmacology DOI Creative Commons

Jie Zou,

Xing Xiao, Ping Zhang

et al.

Frontiers in Pharmacology, Journal Year: 2025, Volume and Issue: 16

Published: May 12, 2025

Background Radiation-induced skin injury (RISI) is a notable complication of cancer radiotherapy, impacting patients’ quality life. Existing interventions mainly address symptoms, with limited success in targeting the fundamental mechanisms. Berberine (BBR), bioactive compound recognized for its anti-inflammatory, antioxidant, and anti-fibrotic characteristics, presents compelling option treating RISI. Methods The molecular targets BBR RISI were identified using Swiss Target Prediction GeneCards databases. A protein-protein interaction (PPI) network was then constructed, core screened Cytoscape plug-in. Molecular functions pathways analyzed through GO KEGG pathway enrichment analyses. Proteomic analysis differential protein expression following treatment. docking validated BBR’s binding to PRKACA PIK3CB. Finally, therapeutic efficacy confirmed irradiated cell animal models. Results pivotal modulating linked inflammation, oxidative stress, tissue repair. Protein histology indicates marked increase epithelial migration proliferation markers (KRT14, KRT16) decrease inflammatory (IL6ST, TNFRSF10B). Enrichment like MAPK cascade development highlights role regeneration. confirms stable key PIK3CB, essential inflammation control. Moreover, treatment promoted cells accelerated wound healing Conclusion demonstrates multi-target potential managing by cellular repair processes. These findings provide foundation future clinical studies optimize dosage delivery, aiming improve outcomes

Language: Английский

Berberine in the treatment of radiation-induced skin injury: insights from proteomics and network pharmacology DOI Creative Commons

Jie Zou,

Xing Xiao, Ping Zhang

et al.

Frontiers in Pharmacology, Journal Year: 2025, Volume and Issue: 16

Published: May 12, 2025

Background Radiation-induced skin injury (RISI) is a notable complication of cancer radiotherapy, impacting patients’ quality life. Existing interventions mainly address symptoms, with limited success in targeting the fundamental mechanisms. Berberine (BBR), bioactive compound recognized for its anti-inflammatory, antioxidant, and anti-fibrotic characteristics, presents compelling option treating RISI. Methods The molecular targets BBR RISI were identified using Swiss Target Prediction GeneCards databases. A protein-protein interaction (PPI) network was then constructed, core screened Cytoscape plug-in. Molecular functions pathways analyzed through GO KEGG pathway enrichment analyses. Proteomic analysis differential protein expression following treatment. docking validated BBR’s binding to PRKACA PIK3CB. Finally, therapeutic efficacy confirmed irradiated cell animal models. Results pivotal modulating linked inflammation, oxidative stress, tissue repair. Protein histology indicates marked increase epithelial migration proliferation markers (KRT14, KRT16) decrease inflammatory (IL6ST, TNFRSF10B). Enrichment like MAPK cascade development highlights role regeneration. confirms stable key PIK3CB, essential inflammation control. Moreover, treatment promoted cells accelerated wound healing Conclusion demonstrates multi-target potential managing by cellular repair processes. These findings provide foundation future clinical studies optimize dosage delivery, aiming improve outcomes

Language: Английский

Citations

0